George Tidmarsh, PhD, has 22 years of experience in biotechnology, which include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla Pharmaceuticals, he served as the chief executive officer of Solana Therapeutics, Inc. Previously, Dr. Tidmarsh served as the chief executive officer of Horizon Pharma, Inc., (NASDAQ: HZNP), a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of conditions such as osteoarthritis and rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) and held senior positions at Coulter Pharmaceutical, Inc.